In vitro model at centre of antimicrobial drug development

Hollow Fibre Infection Models are innovative and versatile tools to expedite and de-risk the development of new antimicrobial therapies.

In the battle against AMR, researchers are exploring innovative ways to get new drugs to the market. The in vitro Hollow Fibre Infection Model (HFIM) plays an important role in this process, helping both the characterization of new drugs and drug combinations, and the push to get them through clinical trials to approval.

The key to de-risking and expediting the development of new antimicrobial drugs is understanding the relationship between exposure to an antimicrobial compound (pharmacokinetics; PK), and the impact of that exposure on the target microbe (pharmacodynamics; PD). This understanding allows for optimized drug dosing to achieve efficacy and avoid resistance, which minimizes the risk of clinical trial failure.